Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on Business magazine’s fifth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity.

The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks. The ranked companies have made tangible and organizational progress related to executive gender parity.

“Recognizing the achievements of companies that effectively address the challenges of executive gender parity represents a pivotal stride forward," says Dawn Calleja, the editor of Report on Business magazine. "Although there’s always more that can be done, the businesses showcased here serve as catalyst for corporate Canada, inspiring them to progress toward gender parity and, in turn, cultivate exceptional enterprises."

“We are honoured to see once again Knight Therapeutics Inc. included on the Globe and Mail’s Report on Canada’s Women Lead Here as one of the leading companies in executive gender diversity in corporate Canada and specialty pharmaceutical sector,” said Samira Sakhia, President and Chief Executive Officer of Knight. “Our commitment to diversity and inclusion is ingrained in our core values, and we actively uphold it every day, both within our company and in our dedicated service to patients”.

For the 2024 ranking, Report on Business conducted a journalistic analysis of approximately 500 large publicly-traded Canadian companies based on revenue, evaluating the ratio of female-identifying to male-identifying executives in the top three tiers of executive leadership. The resultant data was applied to a weighted formula that also factored in company performance, diversity and year-to-year change.

In total, 97 companies earned the 2024 Women Lead Here seal, with a combined average of 45% of executive roles held by female-identifying individuals.

The 2024 Women Lead Here list is published in the April 2024 issue of Report on Business magazine, distributed with The Globe and Mail on March 30, 2024 and online at

About The Globe and Mail
The Globe and Mail is Canada’s foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.2 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.9 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2023, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact: 
Knight Therapeutics Inc. 
Samira SakhiaArvind Utchanah
President & Chief Executive OfficerChief Financial Officer
T: 514.484.4483T. +598.2626.2344
F: 514.481.4116 
Email: IR@knighttx.comEmail:
Website: www.knighttx.comWebsite: